Objective:

To explore how digital twins can address unmet needs in rare disease clinical development and improve patient outcomes.

Approach:

Key Findings:

• 72% of rare diseases have genetic origins and low prevalence rates, complicating patient recruitment and trial design.
• Digital twins can reduce reliance on traditional trial designs and improve the understanding of rare disease populations, leading to better-targeted therapies.
• Predictive analysis can enhance site selection for clinical trials, leading to faster recruitment and more efficient use of resources.

Interpretation:

Digital twins represent a transformative approach in rare disease research, enabling more efficient clinical development and better patient outcomes through tailored interventions.

Limitations:

• Limited historical data for rare diseases can still pose challenges, particularly in establishing benchmarks.
• The effectiveness of digital twins depends on the quality of the underlying data, and ethical concerns regarding data use must be addressed.

Conclusion:

Embracing digital twins is essential for modernizing rare disease diagnostics and clinical development, as they offer innovative solutions to longstanding challenges.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.